{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:04:03Z","timestamp":1787666643268,"version":"build-2736575974"},"reference-count":38,"publisher":"XMLink","issue":"32","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A5A2030333"],"award-info":[{"award-number":["NRF-2021R1A5A2030333"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HG22C0094"],"award-info":[{"award-number":["HG22C0094"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jkms.org"],"crossmark-restriction":false},"short-container-title":["J Korean Med Sci"],"DOI":"10.3346\/jkms.2023.38.e250","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T05:05:26Z","timestamp":1690434326000},"update-policy":"https:\/\/doi.org\/10.3346\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea"],"prefix":"10.3346","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-2786","authenticated-orcid":false,"given":"Youngji","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-1144","authenticated-orcid":false,"given":"Sun Bean","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-3668","authenticated-orcid":false,"given":"Jaehun","family":"Jung","sequence":"additional","affiliation":[{"name":"Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea."},{"name":"Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","published-online":{"date-parts":[[2023]]},"reference":[{"issue":"1","key":"10.3346\/jkms.2023.38.e250_ref1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12929-022-00852-9","volume":"29","author":"Kumari","year":"2022","journal-title":"J Biomed Sci"},{"key":"10.3346\/jkms.2023.38.e250_ref2","doi-asserted-by":"crossref","first-page":"112816","DOI":"10.1016\/j.envres.2022.112816","volume":"209","author":"Khandia","year":"2022","journal-title":"Environ Res"},{"issue":"23","key":"10.3346\/jkms.2023.38.e250_ref3","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2023.38.e250_ref4","unstructured":"Food and Drug Administration (US). FDA authorizes revisions to Evusheld dosing. Updated 2022. Accessed September 20, 2022.  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-revisions-evusheld-dosing"},{"issue":"21","key":"10.3346\/jkms.2023.38.e250_ref5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2023.38.e250_ref6","unstructured":"Food and Drug Administration (US). Fact sheet for healthcare providers: emergency use authorization of sotrovimab. Updated 2022. Accessed September 20, 2022.  https:\/\/www.fda.gov\/media\/149534\/download#:~:text=Sotrovimab%20is%20authorized%20for%20use,who%20are%20at%20high%20risk.2021"},{"key":"10.3346\/jkms.2023.38.e250_ref7","unstructured":"Fred Hutchinson Cancer Center. Pharmacokinetics of sotrovimab as pre-exposure prophylaxis for COVID-19 in hematopoietic stem cell transplant recipients, COVIDMAB study. Updated 2023. Accessed March 1, 2023.  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05135650"},{"issue":"10","key":"10.3346\/jkms.2023.38.e250_ref8","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/v14102278","volume":"14","author":"Totschnig","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"10.3346\/jkms.2023.38.e250_ref9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.3346\/jkms.2023.38.e250_ref10","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.3346\/jkms.2022.37.e189","volume":"37","author":"Jo","year":"2022","journal-title":"J Korean Med Sci"},{"key":"10.3346\/jkms.2023.38.e250_ref11","unstructured":"Centers for Disease Control and Prevention (US). COVID-19 vaccines for people who are moderately or severely immunocompromised. Updated 2022. Accessed September 20, 2022.  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html"},{"key":"10.3346\/jkms.2023.38.e250_ref12","unstructured":"National Institutes of Health (US). Prioritization of anti-SARS-CoV-2 Therapies for the treatment and prevention of COVID-19 when there are logistical or supply constraints. Updated 2022. Accessed September 20, 2022.  https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/prioritization-of-therapeutics\/"},{"key":"10.3346\/jkms.2023.38.e250_ref13","unstructured":"Centers for Disease Control and Prevention (US). Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Updated 2022. Accessed September 20, 2022.  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html"},{"key":"10.3346\/jkms.2023.38.e250_ref14","unstructured":"Centers for Disease Control and Prevention (US). If you are having a severe allergic reaction to a COVID-19 vaccine. Updated 2022. Accessed September 20, 2022.  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/allergic-reaction.html"},{"key":"10.3346\/jkms.2023.38.e250_ref15","unstructured":"Statistics Korea. Population trends for March 2021. Updated 2021. Accessed September 20, 2022.  https:\/\/kostat.go.kr\/board.es?mid=a10301010000&bid=204&tag=&act=view&list_no=389818&ref_bid="},{"key":"10.3346\/jkms.2023.38.e250_ref16","unstructured":"Health Insurance Review & Assessment Service (KR). Healthcare bigdata hub. Updated 2022. Accessed September 20, 2022.  https:\/\/opendata.hira.or.kr\/home.do"},{"key":"10.3346\/jkms.2023.38.e250_ref17","unstructured":"Korea Disease Control and Prevention Agency. Results of weekly analysis of adverse events after COVID-19 vaccination (week 62). Updated 2022. Accessed September 20, 2022.  https:\/\/ncv.kdca.go.kr\/board.es?mid=a11707010000&bid=0032&act=view&list_no=767&tag=&nPage=3"},{"issue":"5","key":"10.3346\/jkms.2023.38.e250_ref18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"Sassi","year":"2006","journal-title":"Health Policy Plan"},{"issue":"7","key":"10.3346\/jkms.2023.38.e250_ref19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/ajt.15941","volume":"20","author":"Pereira","year":"2020","journal-title":"Am J Transplant"},{"key":"10.3346\/jkms.2023.38.e250_ref20","unstructured":"Washington State Department of Health. COVID-19 cases, hospitalizations, and deaths by vaccination status Washington State Department of Health. Published 2022. Accessed September 20, 2022.  https:\/\/doh.wa.gov\/emergencies\/covid-19\/data-dashboard#downloads"},{"issue":"1","key":"10.3346\/jkms.2023.38.e250_ref21","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1038\/s41598-021-87640-x","volume":"11","author":"Pifarr\u00e9 I Arolas","year":"2021","journal-title":"Sci Rep"},{"key":"10.3346\/jkms.2023.38.e250_ref22","first-page":"33","volume":"30","author":"Parra","year":"2022","journal-title":"Elder Law J"},{"issue":"5","key":"10.3346\/jkms.2023.38.e250_ref23","doi-asserted-by":"crossref","first-page":"e2014746118","DOI":"10.1073\/pnas.2014746118","volume":"118","author":"Andrasfay","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3346\/jkms.2023.38.e250_ref24","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"issue":"27","key":"10.3346\/jkms.2023.38.e250_ref25","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.3346\/jkms.2020.35.e219","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.3346\/jkms.2023.38.e250_ref26","unstructured":"This treatment can protect vulnerable people from COVID. But many don\u2019t know about it. Updated 2022. Accessed September 20, 2022.  https:\/\/www.latimes.com\/california\/story\/2022-03-06\/covid-antibody-treatment-obstacles"},{"issue":"10241","key":"10.3346\/jkms.2023.38.e250_ref27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.3346\/jkms.2023.38.e250_ref28","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/bjh.16801","volume":"190","author":"Mart\u00edn-Moro","year":"2020","journal-title":"Br J Haematol"},{"issue":"22","key":"10.3346\/jkms.2023.38.e250_ref29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.15585\/mmwr.mm7022a2","volume":"70","author":"Chanda","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.3346\/jkms.2023.38.e250_ref30","unstructured":"National Institutes of Health (US). Prevention of SARS-CoV-2 infection. Updated 2022. Accessed September 20, 2022.  https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/prevention-of-sars-cov-2\/"},{"key":"10.3346\/jkms.2023.38.e250_ref31","doi-asserted-by":"crossref","first-page":"o2021","DOI":"10.1136\/bmj.o2021","volume":"378","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"10.3346\/jkms.2023.38.e250_ref32","unstructured":"Food and Drug Administration (US). FDA announces Evusheld is not currently authorized for emergency use in the U.S. Updated 2023. Accessed March 10, 2023.  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us"},{"issue":"3","key":"10.3346\/jkms.2023.38.e250_ref33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"issue":"6579","key":"10.3346\/jkms.2023.38.e250_ref34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"Park","year":"2022","journal-title":"Science"},{"key":"10.3346\/jkms.2023.38.e250_ref35","unstructured":"Food and Drug Administration (US). Letter of authorization for emergency use of REGEN-CoV reissue. Updated 2022. Accessed February 11, 2022.  https:\/\/www.fda.gov\/media\/145610\/download"},{"issue":"8","key":"10.3346\/jkms.2023.38.e250_ref36","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jval.2022.03.016","volume":"25","author":"Dijk","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.3346\/jkms.2023.38.e250_ref37","first-page":"555","volume":"28","author":"Jovanoski","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.3346\/jkms.2023.38.e250_ref38","doi-asserted-by":"crossref","first-page":"e228632","DOI":"10.1001\/jamanetworkopen.2022.8632","volume":"5","author":"Flaxman","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Korean Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jkms.org\/pdf\/10.3346\/jkms.2023.38.e250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2023.38.e250","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2023.38.e250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:33:27Z","timestamp":1691973207000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2023.38.e250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":38,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3346\/jkms.2023.38.e250","relation":{},"ISSN":["1011-8934","1598-6357"],"issn-type":[{"value":"1011-8934","type":"print"},{"value":"1598-6357","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"2022-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2023 The Korean Academy of Medical Sciences.","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}],"article-number":"e250"}}